Pargeverine

Pargeverine

SCHEMBL2111437

C#CCOC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.51
CYP2D6 P10635 3/20 0.51
ALDH1A1 P00352 2/20 0.51
POLB P06746 3/20 0.49
CHRM1 P11229 6/20 0.47
CHRM2 P08172 5/20 0.47
CHRM3 P20309 5/20 0.47
CHRM4 P08173 3/20 0.45
CHRM5 P08912 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pargeverine SCHEMBL30728632 0.99 CYP3A4 (0.53) CYP3A4CYP2D6ALDH1A1POLBCHRM1
Dimenoxadol SCHEMBL25993 0.85 CYP3A4 (0.68) CYP3A4CYP2D6ALDH1A1POLBCHRM1
Dimenoxadol SCHEMBL2886211 0.84 CYP3A4 (0.70) CYP3A4CYP2D6ALDH1A1POLBCHRM1
Dimenoxadol SCHEMBL79044 0.84 CYP3A4 (0.70) CYP3A4CYP2D6ALDH1A1POLBCHRM1
Dimenoxadol SCHEMBL5854258 0.83 CYP3A4 (0.69) CYP3A4CYP2D6ALDH1A1POLBCHRM1
Dimenoxadol SCHEMBL2204879 0.82 CYP3A4 (0.67) CYP3A4CYP2D6ALDH1A1POLBCHRM1
Denaverine SCHEMBL147346 0.80 CYP3A4 (0.52) CYP3A4CYP2D6ALDH1A1POLBCHRM1
Denaverine SCHEMBL9569397 0.79 CYP3A4 (0.54) CYP3A4CYP2D6ALDH1A1POLBCHRM1
SCHEMBL8134540 0.76 ALDH1A1 (0.50) CYP3A4CYP2D6ALDH1A1POLBCHRM1
SCHEMBL8134339 0.76 CHRM1 (0.71) CYP3A4CYP2D6ALDH1A1POLBCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281596-A1 PHARMACEUTICAL COMBINATION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMODIC AGENT DIFFUCAP CHEMOBRAS QUÍMICA E FARMACÊUTICA LTDA. (BR) 2017-10-05 US claimed
EP-3195864-A1 PHARMACEUTICAL COMPOSITION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMOSDIC AGENT Diffucap Chemobras Quimica E Farmaceutica Ltda. (BR) 2017-07-26 EP claimed
US-20150150953-A1 PHARMACEUTICAL COMPOSITION ADAPTED FOR ORAL ADMINISTRATION AND THE PROCESS FOR ITS PREPARATION, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, BASED ON AN INTESTINAL MOTILITY MODIFIER AND a-D-GALACTOSIDASE POSI VISIONARY SOLUTIONS LLP (GB) 2015-06-04 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2014141075-A1 COMBINATIONS WITH PROBIOTICS FOR RESTORING ALTERATIONS IN INTESTINAL FUNCTION SIEGFRIED RHEIN S.A. DE C.V. (MX) 2014-09-18 WO claimed
US-20130344145-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF POSI VISIONARY SOLUTIONS LLP (GB) 2013-12-26 US claimed
CN-103429237-A Orally administered pharmaceutical composition for treating irritable bowel syndrome comprising intestinal motility regulator, gas retention preventing agent and digestive enzyme, and preparation method thereof POSI VISIONARY SOLUTIONS LLP 2013-12-04 CN claimed
CN-103392000-A Orally administered pharmaceutical composition comprising intestinal motility modulator and alpha-D-galactosidase for preventing and treating irritable bowel syndrome and preparation method thereof POSI VISIONARY SOLUTIONS LLP 2013-11-13 CN claimed
EP-2641968-A2 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER AND -D-GALACTOSIDASE Posi Visionary Solutions LLP (GB) 2013-09-25 EP claimed
EP-2641598-A2 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF Posi Visionary Solutions LLP (GB) 2013-09-25 EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-20230390224-A1 UNITARY ORAL DOSAGE FORM IN BASE OF SPHERICAL AND/OR SPHEROIDAL SHAPED PARTICLES ATOMIC PHARMACEUTICS INC. (US) 2023-12-07 US disclosed
WO-2023235542-A1 UNITARY ORAL DOSAGE FORM IN BASE OF SPHERICAL AND/OR SPHEROIDAL SHAPED PARTICLES ATOMIC PHARMACEUTICS INC. (US) 2023-12-07 WO disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed